These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 1300215)
1. Demonstration of the reproducibility of treatment efficacy from a single multicenter trial. Huster WJ; Louv WC J Biopharm Stat; 1992; 2(2):219-38. PubMed ID: 1300215 [TBL] [Abstract][Full Text] [Related]
2. Testing for consistency in a single multicenter trial. Chinchilli VM; Bortey EB J Biopharm Stat; 1991; 1(1):67-80. PubMed ID: 1844692 [TBL] [Abstract][Full Text] [Related]
4. Test homogeneity of odds ratio in a randomized clinical trial with noncompliance. Lui KJ; Chang KC J Biopharm Stat; 2009 Sep; 19(5):916-32. PubMed ID: 20183452 [TBL] [Abstract][Full Text] [Related]
5. Pemetrexed in malignant pleural mesothelioma. Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163 [TBL] [Abstract][Full Text] [Related]
6. Analysis of homogeneity of treatment effect in adaptive multicenter clinical trials. Chen L; Tamura RN J Biopharm Stat; 1998 Mar; 8(1):55-67. PubMed ID: 9547427 [TBL] [Abstract][Full Text] [Related]
7. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Kane RC; Farrell AT; Sridhara R; Pazdur R Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588 [TBL] [Abstract][Full Text] [Related]
8. Estimation of the treatment difference in multicenter trials. Fedorov V; Jones B; Jones M; Zhigljavsky A J Biopharm Stat; 2004 Nov; 14(4):1037-63. PubMed ID: 15587979 [TBL] [Abstract][Full Text] [Related]
10. Reproducibility probability in clinical trials. Shao J; Chow SC Stat Med; 2002 Jun; 21(12):1727-42. PubMed ID: 12111908 [TBL] [Abstract][Full Text] [Related]
11. Estimation of the combined response to treatment in multicenter trials. Dragalin V; Fedorov V; Jones B; Rockhold F J Biopharm Stat; 2001 Nov; 11(4):275-95. PubMed ID: 12018780 [TBL] [Abstract][Full Text] [Related]
12. Meta-analyses and adaptive group sequential designs in the clinical development process. Jennison C; Turnbull BW J Biopharm Stat; 2005; 15(4):537-58. PubMed ID: 16022162 [TBL] [Abstract][Full Text] [Related]
13. Sample size allocation to regions in a multiregional trial. Uesaka H J Biopharm Stat; 2009 Jul; 19(4):580-94. PubMed ID: 20183427 [TBL] [Abstract][Full Text] [Related]
14. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. Tsimberidou AM; Braiteh F; Stewart DJ; Kurzrock R J Clin Oncol; 2009 Dec; 27(36):6243-50. PubMed ID: 19826112 [TBL] [Abstract][Full Text] [Related]